Authors
Latest:
MiR-34a Link to PD-L1 May Mean New Immunotherapy in NSCLCTwo presentations at this year’s American Association for Cancer Research (AACR) annual meeting linked a specific microRNA (miRNA), miR-34a, to an active area in immunotherapy, programed cell death-1 (PD-1) protein and its ligand, PD-L1.
Latest:
Hypogammaglobulinemia and Abiraterone Therapy for Metastatic Prostate CancerDescription of 3 cases whereby significant septic complications occurred in the setting of abiraterone use that were associated with hypogammaglobulinemia.
Latest:
Dr. Chandra P. Belani on the Importance of Immunotherapies in Treating Lung CancerChandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, talks about how immunotherapies targeting PD-L1 and PD-1 are showing activity in lung cancer.
Latest:
Clinical Outcomes and Quality of Life in Ovarian CancerCharles A. (Trey) Leath III, MD, associate professor, gynecologic oncology, University of Alabama Birmingham Cancer Center, discusses a study that examined clinical outcomes and quality of life in ovarian cancer.
Latest:
Exploring Celecoxib for the Treatment of Breast CancerCharles Coombes, MD, professor of medical oncology, Imperial College London, discusses a study of celecoxib versus placebo in primary breast cancer patients.
Latest:
Geyer on Managing Toxicities of Olaparib in BRCA+/HER2- Breast CancerCharles Geyer, MD, advises his peers on how to manage the grade 3 or higher toxicities and any serious adverse events seen in the clinical trial setting with adjuvant olaparib.
Latest:
Investigating Immunotherapy Treatment in Renal Cell CarcinomaCharles G. Drake, MD, PhD, director of Genitourinary Oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting.
Latest:
Use of ARN-509 in Prostate CancerCharles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the use of ARN-509 and its efficacy in treating prostate cancer.
Latest:
The Results of the IBIS II TrialCharles L. Shapiro, MD, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.
Latest:
Dr. Charles M. Perou on the Evolution of Precision Medicine in Breast Cancer​Charles M. Perou, PhD, professor of Genetics, Pathology & Laboratory Medicine, Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses precision medicine in breast cancer and currently known biomarkers.
Latest:
Stimulating the Immune System With Coxsackievirus in Advanced Cancer PatientsCharles M. Rudin, MD, PhD, chief, thoracic oncology, Memorial Sloan Kettering Cancer, discusses a study of intravenously delivered coxsackievirus A21 with pembrolizumab to treat patients with advanced cancers.
Latest:
Dr. Charles Perou on Molecular Differences in Lobular Breast CancerPerou says this research also found three expression subtypes within lobular breast cancer, one of which showed a proliferative phenotype and portended a slightly worse prognosis.
Latest:
The Future Treatment Landscape of Gastric CancerCharles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, discusses what he envisions for the future treatment landscape of gastric cancer.
Latest:
Closing Thoughts on Recent Data in Non–Small Cell Lung CancerRohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key NSCLC data updates discussed following the 2023 ASCO Annual Meeting.
Latest:
Use of Anthracyclines Plus Taxanes Found to be Beneficial in Early, HER2-Negative Breast CancerTreatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer.
Latest:
Case 2: Safety Considerations in the Use of T-DXd for HER2+ mBCA key opinion leader in oncology shares expert perspectives on safety considerations when treating patients with T-DXd in the second-line setting for HER2+ mBC.
Latest:
CDK4&6 Inhibitors Revolutionize Hormone-Positive Breast Cancer CareDenise A. Yardley, MD, discusses the promise of CDK4&6 inhibitors in estrogen receptor (ER)-positive breast cancer, as well as the potential with immunotherapy agents.
Latest:
Effective Options Arise for Patients With ALK-Positive NSCLCNew treatments that are currently in development have begun to show promise for patients diagnosed with ALK-positive non-small-cell lung cancer (ALK+ NSCLC), a subset of patients who have historically faced poor outcomes.
Latest:
Searching for Positives in Triple-Negative Breast CancerTreatments for triple-negative breast cancer (TNBC) have made significantly less progress in comparison with other subtypes.
Latest:
FOLFOXIRI plus Bevacizumab for Metastatic Colorectal CancerChiara Cremolini, MD, discusses the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as for patients with metastatic colorectal cancer.
Latest:
Achieving a Higher pCR Rate With Nab-Paclitaxel in Breast CancerChristian Jackisch, MD, PhD, Professor of Obstetrics and Gynecology and Head of the Department of Obsterics and Gynaecology, Sana Klinikum Offenbach in Germany, discusses results of the GeparSepto study, as well as how a higher pathologic complete response (pCR) rate is achieved with nab-paclitaxel (Abraxane) in breast cancer.
Latest:
Dr. Christiane Kuhl Discusses Breast MRI Screening of Women at Average Risk of Breast CancerChristiane K. Kuhl, MD, Department of Diagnostic and Interventional Radiology, RWTH University of Aachen, discusses an observational cohort study looking at breast MRI screening of women at average risk of breast cancer.
Latest:
Dr. Christiane Kuhl on the Overdiagnosis of Breast CancerChristiane Kuhl, MD, Professor of Radiology and Vice Chairman of the Radiological department, Director of the Division of Oncologic Imaging and Interventional Therapy, Bonn University, talks about the over diagnosis of breast cancer through mammography screenings.
Latest:
Targeted Therapies End the Dry Spell in AML Drug DevelopmentTargeted agents are routinely used to treat many cancers and have improved outcomes for patients with solid tumors and hematological malignancies alike. Recently, targeted therapies made their way into the armamentarium for acute myeloid leukemia, representing the first therapeutic advances for AML in decades.
Latest:
Recent Studies Point to a Greater Role for PARP Inhibitors in Solid TumorsThe early development of PARP inhibitors in 2003 focused on their use in combination with cytotoxic chemotherapy agents, but this was eventually abandoned because of excess toxicity.
Latest:
Epidemic in Sex-Related Oral Cancer Highlights Need for GuidelinesOver the past few decades, the annual incidence of OPSCC has increased sharply in several countries, including in the United States.
Latest:
Study Validates Noninvasive Urinary Cell-Free DNA Assay for Urothelial Bladder CancerA recent study has shown that extracting cell-free DNA from urine is a highly effective technique for analyzing the genetic profile of urothelial bladder cancers.
